2017-18 HSC Section 3 Green Book

Hsueh et al

106. Di Nisio M, Middeldorp S, Bu¨ller HR. Direct thrombin inhi- bitors. N Engl J Med . 2005;353:1028-1040. 107. Brown C, Joshi B, Faraday N, et al. Emergency cardiac sur- gery in patients with acute coronary syndromes: a review of the evidence and perioperative implications of medical and mechanical therapeutics. Anesth Analg . 2011;112:777-799. 108. Wysokinski WE, McBane RD 2nd. Periprocedural bridging management of anticoagulation. Circulation . 2012;126:486-490. 109. Landenhed M, Johansson M, Erlinge D, Olsson ML, Bjursten H. Fondaparinux or enoxaparin: a comparative study of post- operative bleeding in coronary artery bypass grafting surgery. Scand Cardiovasc J . 2010;44:100-106. 110. Salem DN, O’Gara PT, Madias C, Pauker SG. Valvular and structural heart disease: American College of Chest Physicians evidence-based clinical practice guidelines (8th edition). Chest . 2008;133(6):593S-629S. 111. Siegal D, Yudin J, Kaatz S, et al. Periprocedural heparin brid- ging in patients receiving vitamin K antagonists: systematic review and meta-analysis of bleeding and thromboembolic rates. Circulation . 2012;126:1630-1609. 112. BRIDGE Study Investigators. Bridging anticoagulation: is it needed when warfarin is interrupted around the time of a sur- gery or procedure? Circulation . 2012;125:e496-e498. 113. Dunn AS, Spyropoulos AC, Turpie AG. Bridging therapy in patients on long-term oral anticoagulants who require sur- gery: the Prospective Peri-operative Enoxaparin Cohort Trial (PROSPECT). J Thromb Haemost . 2007;5:2211-2218. 114. Carmignani L, Picozzi S, Bozzini G, et al. Transrectal ultrasound-guided prostate biopsies in patients taking aspirin for cardiovascular disease: a meta-analysis. Transfus Apheresis Sci . 2011;45:275-280. 115. Atwell TD, Smith RL, Hesley GK, et al. Incidence of bleed- ing after 15,181 percutaneous biopsies and the role of aspirin. AJR Am J Roentgenol . 2010:194:784-789. 116. Wahidi MM, Garland R, Feller-Kopman D, et al. Effect of clopidogrel with and without aspirin on bleeding following transbronchial lung biopsy. Chest . 2005;127:961-964. 117. Eikelboom JW, Hirsh J, Spencer FA, Baglin TP, Weitz JI. Antiplatelet drugs: antithrombotic therapy and prevention of thrombosis, 9th ed. American College of Chest Physicians evidence-based clinical practice guidelines. Chest . 2012; 141(2):e89S-119S. 118. Fitchett D, Mazer CD, Eikelboom J, Verma S. Antiplatelet therapy and cardiac surgery: review of recent evidence and clinical implications. Can J Cardiol . 2013;29:1042-1047. 119. MacLean S, Mulla S, Akl EA, et al. Patient values and pre- ferences in decision making for antithrombotic therapy: a sys- tematic review. Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest . 2012; 141(2):e1S-e23S.

88. Sarkar S, Mehta SA, Tiwari J, Mehta AR, Mehta MS. Complications following surgery for cancer of the larynx and pyriform fossa. J Surg Oncol . 1990;43:245-249. 89. Stell PM. Catastrophic haemorrhage after major neck sur- gery. Br J Surg . 1969;56:525-527. 90. Shemen LJ, Spiro RH. Complications following laryngect- omy. Head Neck Surg . 1986;8:185-191. 91. Cole SM, Patterson MB, Cupp CL. Tonsillectomy in the anticoa- gulated patient. Ann Otol Rhinol Laryngol . 2007;116:589-593. 92. Windfuhr JP, Chen YS, Remmert S. Hemorrhage following tonsillectomy and adenoidectomy in 15,218 patients. Otolaryngol Head Neck Surg . 2005;132:281-286. 93. Randall DA, Hoffer ME. Complications of tonsillectomy and adenoidectomy. Otolaryngol Head Neck Surg . 1998;118:61-68. 94. Carmody D, Vamadevan T, Cooper SM. Post tonsillectomy haemorrhage. J Laryngol Otol . 1982;96:635-638. 95. Chowdhury K, Tewfik TL, Schloss MD. Post-tonsillectomy and adenoidectomy hemorrhage. J Otolaryngol . 1988;17:46-49. 96. Dzik WS. Reversal of drug-induced anticoagulation: old solu- tions and new problems. Transfusion . 2012;52(suppl 1):45S- 55S. 97. Schulman S, Elbazi R, Zondag M, O’Donnell M. Clinical factors influencing normalization of prothrombin time after stopping warfarin: a retrospective cohort study. Thromb J . 2008;6:15. 98. White RH, McKittrick T, Hutchinson R, Twitchell J. Temporary discontinuation of warfarin therapy: changes in the international normalized ratio. Ann Intern Med . 1995;122:40-42. 99. Kearon C, Hirsh J. Management of anticoagulation before and after elective surgery. N Engl J Med . 1997;336:1506-1511. 100. Woods K, Douketis JD, Kathirgamanathan K, Yi Q, Crowther MA. Low-dose oral vitamin K to normalize the international normalized ratio prior to surgery in patients who require temporary interruption of warfarin. J Thromb Thrombolysis . 2007;24:93-97. 101. Holbrook A, Schulman S, Witt DM, et al. Evidence-based management of anticoagulant therapy: antithrombotic therapy and prevention of thrombosis, 9th ed. American College of Chest Physicians evidence-based clinical practice guidelines. Chest . 2012;141(2):e152S-e184S. 102. van Ryn J, Stangier J, Haertter S, et al. Dabigatran etexilate—a novel, reversible, oral direct thrombin inhibitor: interpretation of coagulation assays and reversal of anticoagu- lant activity. Thromb Haemost . 2010;103:1116-1127. 103. Hankey GJ, Eikelboom JW. Dabigatran etexilate: a new oral thrombin inhibitor. Circulation . 2011;123:1436-1450. 104. Stangier J, Rathgen K, Sta¨hle H, Mazur D. Influence of renal impairment on the pharmacokinetics and pharmacodynamics of oral dabigatran etexilate: an open-label, parallel-group, single-centre study. Clin Pharmacokinet . 2010;49:59-68. 105. Crowther MA, Warkentin TE. Managing bleeding in anticoa- gulated patients with a focus on novel therapeutic agents. J Thromb Haemost . 2009;7(suppl 1):107-10.

193